Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- Nonobstructive CAD remains vexing, especially in women
-
- FDA approves ready-to-use version of bivalirudin for PCI
- Percutaneous heart pumps gain new indications
- AHA: Mortality from uncontrolled BP rises; CVD leading cause of death in US
- CVD risk may increase with breast cancer treatment
- Elevated high-sensitivity cardiac troponin predicts incident HF
- In-hospital mortality in AF more prevalent in rural hospitals
- Migraines increase risk for CVD
- Stroke, CHD risk persist with minimal cigarette consumption
-
- Predictors, safety of next-day discharge after TAVR confirmed
- Program improves heart-healthy restaurant offerings in rural areas
- Rates of HF, common cancers similar in socioeconomically deprived patients
- Readmissions higher in women with acute MI, cardiogenic shock
- Replacing sitting with standing may aid in long-term weight loss
- Survival decreases in in-hospital cardiac arrest during off-hours
- In its 15th year, National Wear Red Day increases awareness of women's heart health
- Clot-busting drugs after stroke given less to patients with cancer
-
- Mechanical thrombectomy, IV alteplase recommendations updated in new stroke guidelines
- Medical therapy for PAD making great strides
- Technology may treat fluid overload in congestive HF
- Thrombectomy improved outcomes in patients with stroke, salvageable brain tissue
- Women with PAD may respond differently to DCB treatment
- #SoMe for the busy physician Sheila Sahni, MD; M. Chadi Alraies, MD
- Lipid-lowering therapy for primary prevention of CV events: Navigating the guidelines Scott Yost, PharmD, BCPS; Joshua J. Jacobs, PharmD; Bonnie Kaminsky, PharmD, BCPS; Sarah A. Spinler, PharmD, FCCP, FAHA, FASHP, AACC, BCPS (AQ Cardiology)
- Trial Scorecard: ACS QUIK
-
- Trial Scorecard: DECREASE-PCI
- Trial Scorecard: DEFUSE 3
- Trial Scorecard: DESERVE
- Trial Scorecard: EJECTION-HF
- Trial Scorecard: EXTEND-IA TNK
- Trial Scorecard: LEADLESS
- Trial Scorecard: PROPER